MONOPRIL

Compare MONOPRIL  to:
Compare
Compare

Generic Name for MONOPRIL

Fosinopril sodium 10mg+, 20mg, 40mg; tabs; +scored.

Legal Classification:

Rx

Pharmacological Class for MONOPRIL

ACE inhibitor.

Manufacturer of MONOPRIL

Bristol-Myers Squibb

Indications for MONOPRIL

Hypertension.

Adult dose for MONOPRIL

Initially 10mg once daily. Usual maintenance: 20–40mg daily in single or 2 divided doses; max 80mg/day. If on diuretic: suspend diuretic for 2–3 days before starting if possible; resume diuretic if pressure not controlled with fosinopril alone. If diuretic cannot be discontinued: give 10mg and monitor carefully.

Children's dosing for MONOPRIL

<6yrs (≤50kg): not recommended. ≥6yrs (>50kg): 5–10mg once daily.

Contraindications for MONOPRIL

History of ACEI-associated or other angioedema. Pregnancy (Cat.D in 2nd and 3rd trimesters).

Precautions for MONOPRIL

Salt/volume depletion. Renal or hepatic impairment. Monitor WBCs in renal or collagen vascular disease. CHF. Dialysis (esp. high-flux membrane). Renal artery stenosis. Monitor for hyperkalemia in diabetics. Discontinue if angioedema, laryngeal edema, jaundice, or markedly elevated liver enzymes occurs. Surgery. Pregnancy (Cat.C in 1st trimester). Nursing mothers: not recommended.

Interactions for MONOPRIL

Potentiated by diuretics. Potassium or K+-sparing diuretics may cause hyperkalemia. May increase lithium levels. Separate antacid dosing by 2 hrs. May cause false low serum digoxin measurements.

Adverse Reactions for MONOPRIL

Headache, cough, dizziness, GI upset, hyperkalemia, orthostatic hypotension, angioneurotic edema (discontinue if occurs).

How is MONOPRIL supplied?

Tabs 10mg, 20mg—30, 90, 1000
40mg—30, 90

Related Disease:

Hypertension

Related Resources

FDA warns of reduced Plavix efficacy in poor metabolizers

March 15, 2010

The FDA has notified healthcare professionals and patients that a Boxed Warning has been added to the Plavix (clopidogrel tablets, from Bristol-Myers Squibb and Sanofi) Prescribing Information to include information about reduced Plavix efficacy in patients who are poor metabolizers of Plavix.

Benicar gains expanded indication for treatment of hypertension in children

February 11, 2010

The FDA has approved Benicar (olmesartan medoxomil tablets, from Daiichi Sankyo) for the treatment of hypertension in children and adolescents 6-16 years of age.

Exel/Exelint infusion set needles recalled

January 26, 2010

FDA notified healthcare professionals of a Class I recall of Exel/Exelint Huber needles, Exel/Exelint Huber Infusion Sets, and Exel/Exelint "Securetouch+" Safety Huber Infusion Sets due to 'coring,' the cutting or dislodging of silicone cores or slivers from the ports into which they are inserted).

Cleviprex injection recalled due to presence of particulate matter

December 17, 2009

The FDA and The Medicines Company have notified healthcare professionals of a voluntary nationwide recall of 11 lots of Cleviprex (clevidipine butyrate) injection emulsion due to the presence of visible particulate matter observed in some vials.

Clonidine ER Suspension and Clonidine ER Tablets approved

December 07, 2009

Tris Pharma announced that the FDA has approved Clonidine ER suspension and Clonidine ER tablets, both of which utilize its proprietary OralXR+ platform technology to allow for once daily dosing.